EP Vantage Pharma & Biotech 2016 in Review

The annual EP Vantage Pharma & Biotech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the pharma and biotech sector during 2016.

For the world’s drug makers 2016 was a year of two halves. Activity like deal-making and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. 

Key findings include:

  • The Nasdaq Biotechnology Index ended in the red for the first time since 2008

  • The $98.7bn spent on pharma & biotech acquisitions in 2016 was less than half that of the biotech boom’s peak in 2014

  • The fourth quarter saw three venture rounds breaking the $200m barrier; with Moderna Therapeutics exceeding $1bn

Download Report